MEMBERS Trust Co trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,209 shares of the company’s stock after selling 890 shares during the period. Johnson & Johnson makes up about 0.1% of MEMBERS Trust Co’s portfolio, making the stock its 24th biggest position. MEMBERS Trust Co’s holdings in Johnson & Johnson were worth $1,564,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Stelac Advisory Services LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth $108,000. Princeton Capital Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth $141,000. Smart Portfolios LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth $150,000. Fenimore Asset Management Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth $217,000. Finally, Northwest Capital Management Inc purchased a new stake in Johnson & Johnson in the 4th quarter worth $223,000. Institutional investors and hedge funds own 66.80% of the company’s stock.

NYSE JNJ opened at $139.89 on Friday. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. The stock has a market capitalization of $373.89 billion, a price-to-earnings ratio of 17.87, a P/E/G ratio of 2.13 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company had revenue of $20.83 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same quarter in the prior year, the company posted $1.83 earnings per share. Johnson & Johnson’s revenue for the quarter was up 10.6% compared to the same quarter last year. analysts predict that Johnson & Johnson will post 8.14 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were given a $0.90 dividend. The ex-dividend date was Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s payout ratio is currently 49.32%.

Several equities research analysts recently commented on the stock. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, June 12th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Sanford C. Bernstein initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price on the stock. Finally, TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $142.34.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Trading Strategy Examples and Plans

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.